Valérie André

3.9k total citations
103 papers, 1.9k citations indexed

About

Valérie André is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Valérie André has authored 103 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 25 papers in Molecular Biology and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Valérie André's work include Advanced Breast Cancer Therapies (18 papers), Skin Protection and Aging (13 papers) and Lung Cancer Research Studies (8 papers). Valérie André is often cited by papers focused on Advanced Breast Cancer Therapies (18 papers), Skin Protection and Aging (13 papers) and Lung Cancer Research Studies (8 papers). Valérie André collaborates with scholars based in United States, France and United Kingdom. Valérie André's co-authors include Sophie Callies, Odile Damour, Éric Perrier, Matthew P. Goetz, Joohyuk Sohn, Nicolas Béchetoille, Jens Huober, I. Orly, Valérie Cenizo and Masakazu Toi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Biomaterials.

In The Last Decade

Valérie André

98 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Valérie André United States	24	638	525	463	247	214	103	1.9k
Hongwei Wang China	26	520 0.8×	235 0.4×	388 0.8×	158 0.6×	177 0.8×	129	1.7k
Frank Schneider United States	30	902 1.4×	418 0.8×	625 1.3×	67 0.3×	177 0.8×	106	2.7k
Min Wu China	23	947 1.5×	310 0.6×	181 0.4×	139 0.6×	523 2.4×	97	1.8k
Zoltán Nemes Hungary	24	556 0.9×	258 0.5×	727 1.6×	285 1.2×	76 0.4×	59	2.2k
Lucy Liu United States	25	480 0.8×	300 0.6×	167 0.4×	471 1.9×	70 0.3×	71	2.0k
Violetta Filas Poland	15	511 0.8×	530 1.0×	130 0.3×	72 0.3×	230 1.1×	43	1.7k
Jan‐Show Chu Taiwan	25	991 1.6×	503 1.0×	226 0.5×	88 0.4×	369 1.7×	74	2.0k
Sun Young Oh United States	19	480 0.8×	320 0.6×	154 0.3×	338 1.4×	134 0.6×	55	1.5k
Gangwen Han United States	25	1.6k 2.5×	697 1.3×	225 0.5×	276 1.1×	506 2.4×	39	2.9k
Li Teng China	20	435 0.7×	226 0.4×	248 0.5×	135 0.5×	150 0.7×	85	1.4k

Countries citing papers authored by Valérie André

Since Specialization

Citations

This map shows the geographic impact of Valérie André's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Valérie André with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Valérie André more than expected).

Fields of papers citing papers by Valérie André

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Valérie André. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Valérie André. The network helps show where Valérie André may publish in the future.

Co-authorship network of co-authors of Valérie André

This figure shows the co-authorship network connecting the top 25 collaborators of Valérie André. A scholar is included among the top collaborators of Valérie André based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Valérie André. Valérie André is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goetz, Matthew P., İrfan Çiçin, Laura Testa, et al.. (2024). Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. npj Breast Cancer. 10(1). 34–34. 12 indexed citations

O’Shaughnessy, Joyce, Laura Testa, Sara M. Tolaney, et al.. (2023). 274P Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study. Annals of Oncology. 34. S293–S293. 1 indexed citations

Harbeck, Nadia, Priya Rastogi, J. O’Shaughnessy, et al.. (2023). LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. Annals of Oncology. 34. S1256–S1256. 11 indexed citations

Grischke, Eva‐Maria, Antonio Llombart‐Cussac, Masakazu Toi, et al.. (2023). Final Overall Survival Analysis of MONARCH 2: A Phase 3 Trial of Abemaciclib plus Fulvestrant in Patients with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer. Senologie - Zeitschrift für Mammadiagnostik und -therapie. 20(2). e5–e6. 1 indexed citations

Danoux, Louis, et al.. (2022). Regulation of stem cell fate by HSPGs: implication in hair follicle cycling. npj Regenerative Medicine. 7(1). 77–77. 15 indexed citations

Johnston, Stephen, Joyce O’Shaughnessy, Miguel Martín, et al.. (2021). Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. npj Breast Cancer. 7(1). 80–80. 36 indexed citations

Goetz, Matthew P., Meena Okera, Hans Wildiers, et al.. (2021). Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Research and Treatment. 186(2). 417–428. 34 indexed citations

Rugo, Hope S., Véronique Dièras, Javier Cortés, et al.. (2020). Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1. Breast Cancer Research and Treatment. 184(1). 161–172. 3 indexed citations

Kaufman, Peter A., Masakazu Toi, Patrick Neven, et al.. (2019). Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. The Oncologist. 25(2). e243–e251. 51 indexed citations

10.

Ueno, Hideki, Shunsuke Kondo, Shusuke Yoshikawa, et al.. (2018). A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors. Investigational New Drugs. 36(4). 647–656. 20 indexed citations

11.

LoRusso, Patricia, Mrinal M. Gounder, Shadia I. Jalal, et al.. (2017). Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors. Investigational New Drugs. 35(4). 442–450. 16 indexed citations

12.

Costes, L M M, et al.. (2016). 246 Prebiotic stimulation of innate immune system, skin barrier and staphylococci homeostasis. Journal of Investigative Dermatology. 136(9). S203–S203. 1 indexed citations

13.

Natale, Ronald B., Fiona Blackhall, Dariusz M. Kowalski, et al.. (2014). Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study. Journal of Thoracic Oncology. 9(11). 1704–1708. 30 indexed citations

14.

Wiechno, Paweł, Bradley G. Somer, Begoña Mellado, et al.. (2013). A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer. European Urology. 65(3). 516–520. 50 indexed citations

15.

Hong, David S., Razelle Kurzrock, Yun Oh, et al.. (2011). A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer. Clinical Cancer Research. 17(20). 6582–6591. 113 indexed citations

16.

Saleem, Azeem, Julian C. Matthews, Malcolm Ranson, et al.. (2011). Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients. Theranostics. 1. 290–301. 14 indexed citations

17.

Provost, Gabrielle S. Le, Romain Debret, Valérie Cenizo, et al.. (2010). Lysyl Oxidase silencing impairs keratinocyte differentiation in a reconstructed‐epidermis model. Experimental Dermatology. 19(12). 1080–1087. 16 indexed citations

18.

Auxenfans, Céline, Nicolas Builles, Valérie André, et al.. (2008). Matrice poreuse et culture de cellules primaires : un même concept pour la reconstruction cutanée et cornéenne. Pathologie Biologie. 57(4). 290–298. 12 indexed citations

19.

André, Valérie, et al.. (1999). A Comparison of Biological Activities of a New Soya Biopeptide Studied in an In Vitro Skin Equivalent Model and Human Volunteers. International Journal of Cosmetic Science. 21(5). 299–311. 10 indexed citations

20.

André, Valérie, et al.. (1980). Discours de réception à l'Académie. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 131–144. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact